Prostate-Specific Antigen (PSA) Test Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (CLIA Method, ELISA Method) By Application (Screening, Post-treatment Monitoring, Others) and Region Forecast 2019-2030

Prostate-Specific Antigen (PSA) Test Market size was valued at US$ 3,876.9 million in 2023 and is poised to grow at a significant CAGR of 11.9% from 2024-2030. PSA or prostate-specific antigen testing determines the amount of PSA in human blood. The prostate is a tiny gland in a man's reproductive system placed underneath the bladder. Prostate-specific antigen is a glycoprotein released by prostatic epithelial cells, and PSA is either attached to other cells or freely circulates throughout the body. The CLIA method segment is anticipated to grow at a significant CAGR over the forecast years, owing to CLIA solutions being frequently used in identifying chronic diseases such as infectious disease, autoimmune disease, cardiovascular disease, diabetes, obesity, and prostate cancer. CLIA is also utilized for therapeutic medication monitoring by several pharmaceutical corporations and research institutions. Rising awareness of the need for early detection of chronic diseases and increased medication discovery and development operations by pharmaceutical firms are viewed as high-impact key drivers for the Segment. Increase in prostate cancer among men, who are over 50 years of age. Furthermore, the adoption of various assay-based methods and various new inventions for the diagnosis of prostate cancer has raised the demand for industry's growth over the forecasting period.

 Key Developments

• In September 2021: Boston Scientific Corporation, the leading medical device manufacturer, announced that the EPOCH clinical trial of the TheraSphere Y-90 Glass Microspheres successfully met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC) of the liver.